
Keywords: AA; accelerated approval; ALL; acute lymphoblastic leukemia; CCyR; complete cytogenetic response; CLL; chronic lymphocytic lymphoma; CML; chronic myeloid leukemia; CRC; colorectal carcinoma; CR; complete response; CRi; complete response with incomplete bl